| Author | Ranzani, Otavio T. | |
| Author | Hitchings, Matt D. T. | |
| Author | Melo, Rosana Leite de | |
| Author | França, Giovanny V. A. de | |
| Author | Fernandes, Cássia de Fátima R. | |
| Author | Lind, Margaret L. | |
| Author | Torres, Mario Sergio Scaramuzzini | |
| Author | Tsuha, Daniel Henrique | |
| Author | David, Leticia C. S. | |
| Author | Said, Rodrigo F. C. | |
| Author | Almiron, Maria | |
| Author | Oliveira, Roberto D. de | |
| Author | Cummings, Derek A. T. | |
| Author | Dean, Natalie E. | |
| Author | Andrews, Jason R. | |
| Author | Ko, Albert I. | |
| Author | Croda, Julio | |
| Access date | 2022-12-21T17:12:03Z | |
| Available date | 2022-12-21T17:12:03Z | |
| Document date | 2022 | |
| Citation | RANZANI, Otavio T. et al. Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against the Omicron in Brazil. Nature Communications, p. 1-10, 2022. | en_US |
| URI | https://www.arca.fiocruz.br/handle/icict/56134 | |
| Description | These authors contributed equally: Derek A. T. Cummings, Natalie E Dean, Jason R. Andrews, Albert I. Ko, Julio Croda. | en_US |
| Sponsorship | We thank the Pan American Health Organization for its support. No external funding was provided for this study. OTR is funded by a Sara Borrell fellowship (CD19/00110) from the Instituto de Salud Carlos III. OTR acknowledges support from the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa 2019-2023 programme (CEX2018-000806-S) and from the Generalitat de Catalunya through the Centres de Recerca de Catalunya (CERCA) programme. DATC and MDH report a contract from Merck (to the University of Florida) for research unrelated to this manuscript. These institutions had no role in the study design, data collection, data analysis, data interpretation, or
writing of the report. | en_US |
| Language | eng | en_US |
| Publisher | Nature | en_US |
| Rights | open access | en_US |
| Subject in Portuguese | COVID-19 | en_US |
| Subject in Portuguese | Vacinas | en_US |
| Subject in Portuguese | CoronaVac | en_US |
| Subject in Portuguese | Vacina BNT162 | en_US |
| Subject in Portuguese | Estudos de Casos e Controles | en_US |
| Subject in Portuguese | Imunização Secundária | en_US |
| Title | Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil | en_US |
| Type | Article | en_US |
| DOI | 10.1038/s41467-022-33169-0 | |
| Abstract | The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, testnegative, case-control study to estimate VE for homologous and heterologous
(BNT162b2) booster doses in adults who received two doses of CoronaVac in Brazil in the Omicron context. Analyzing 1,386,544 matched-pairs, VE against symptomatic disease was 8.6% (95% CI, 5.6–11.5) and 56.8% (95% CI, 56.3–57.3)
in the period 8–59 days after receiving a homologous and heterologous booster, respectively. During the same interval, VE against severe Covid-19 was 73.6% (95% CI, 63.9–80.7) and 86.0% (95% CI, 84.5–87.4) after receiving a
homologous and heterologous booster, respectively. Waning against severe Covid-19 after 120 days was only observed after a homologous booster. Heterologous booster might be preferable to individuals with completed primary
series inactivated vaccine. | en_US |
| Affilliation | Universitat Pompeu Fabra. Barcelona Institute for Global Health. ISGlobal. Barcelona, Spain / Faculdade de Medicina. Hospital das Clínicas. Heart Institute. Pulmonary Division. São Paulo, SP, Brazil / CIBER Epidemiología y Salud Pública (CIBERESP). Madrid, Spain. | en_US |
| Affilliation | University of Florida. College of Public Health & Health Professions. Department of Biostatistics. Gainesville, FL, USA. | en_US |
| Affilliation | Ministério da Saúde. Secretaria Extraordinária de Enfrentamento à Covid-19. Brasília, DF, Brasil. | en_US |
| Affilliation | Ministério da Saúde. Secretaria de Vigilância em Saúde. Brasília, DF, Brazil. | en_US |
| Affilliation | Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA. | en_US |
| Affilliation | Secretary of Manaus. Municipal Health. Manaus, AM, Brazil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Fiocruz Mato Grosso do Sul. Campo Grande, MS, Brazil. | en_US |
| Affilliation | Pan American Health Organization, Brasilia, DF, Brazil. | en_US |
| Affilliation | Pan American Health Organization, Brasilia, DF, Brazil. | en_US |
| Affilliation | Pan American Health Organization, Brasilia, DF, Brazil. | en_US |
| Affilliation | State University of Mato Grosso do Sul, Dourados, MS, Brazil. | en_US |
| Affilliation | University of Florida. Department of Biology. Gainesville, FL, USA / University of Florida. Emerging Pathogens Institute, Gainesville, FL, USA. | en_US |
| Affilliation | Emory University. Rollins School of Public Health. Department of Biostatistics & Bioinformatics, Atlanta, GA, USA. | en_US |
| Affilliation | Stanford University. Division of Infectious Diseases and Geographic Medicine. Stanford, CA, USA. | en_US |
| Affilliation | Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil. | en_US |
| Affilliation | Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA / Fundação Oswaldo Cruz. Fiocruz Mato Grosso do Sul. Campo Grande, MS, Brazil / Universidade Federal de Mato Grosso do Sul. Campo Grande, MS, Brasil. | en_US |
| Subject | COVID-19 | en_US |
| Subject | Vaccines | en_US |
| Subject | CoronaVac | en_US |
| Subject | BNT162b2 | en_US |
| Subject | Case-control study | en_US |
| Subject | Booster | en_US |
| DeCS | COVID-19 | en_US |
| DeCS | Vacinas | en_US |
| DeCS | CoronaVac | en_US |
| DeCS | Vacina BNT162 | en_US |
| DeCS | Estudos de Casos e Controles | en_US |
| DeCS | Imunização Secundária | en_US |
| xmlui.metadata.dc.subject.ods | 03 Saúde e Bem-Estar | |
